Keystone 65 Select Rx HMO

Keystone 65 Preferred Rx HMO

Personal Choice 65SM Rx PPO

2019 Utilization Management Criteria: Prior Authorization

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN

This document was updated on 11/01/2019. For more recent information or other questions, please contact our Member Help Team: Keystone 65 at 1-800-645-3965, Personal Choice 65 at 1-888-718-3333, Select Option at 1-888-678-7009 or, for TTY/TDD users, 711, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit www.ibxmedicare.com to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2020, and from time to time during the year.

Independence Blue Cross offers Medicare Advantage plans with a Medicare contract. Enrollment in Independence Medicare Advantage plans depends on contract renewal.

Keystone 65: Benefits underwritten by Keystone Health Plan East, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

Personal Choice 65: Benefits underwritten by QCC Insurance Company, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

Y0041_HM_18_70813 IBC8865 (11/19)

There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this "utilization management." These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don't get approval, our plan may not cover the drug. Drugs that require Prior Authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require Step Therapy are listed in *2019 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have Quantity Limits are listed in the *Keystone 65 Select Rx, Keystone 65 Preferred Rx, and Personal Choice 65 Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting www.ibxmedicare.com.

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

How to use this document

This document, along with *2019 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note "PA" in the "Requirements" column of the *Keystone 65 Select Rx, Keystone 65 Preferred Rx, and Personal Choice 65 Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 145. The restriction information includes:

- **Prior Authorization**
  - Covered uses
  - Exclusion criteria
  - Required medical information
  - Age restrictions
  - Prescriber restrictions
  - Coverage duration
  - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions, or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 at 1-800-645-3965, Personal Choice 65 at 1-888-718-3333.

ABILIFY MYCITE

Products Affected

- ABILIFY MYCITE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Both of the following (1) inadequate response or inability to tolerate generic aripiprazole and (2) attestation tracking ingestion of the medication is medically necessary

ABUSE DETERRENT OPIOID

Products Affected

- XTAMPZA ER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of one of the following: (1) Prior use of TWO generic opioids OR (2) BOTH of the following: (a) there is a history of or a potential for drug abuse among the individual or a member of the individual's household AND (b) documentation of current patient-prescriber opioid treatment agreement

ACTEMRA SQ

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists.
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if age is less than 2 years for Polyarticular and Systemic juvenile rheumatoid arthritis and Cytokine release Syndrome. Deny if less than 18 years for all other Indications
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist
Coverage Duration	Indefinite
Other Criteria	For Polyarticular Juvenile rheumatoid arthritis, Systemic onset Juvenile chronic arthritis, and moderate to severe rheumatoid arthritis: documentation of inadequate response or inability to tolerate BOTH adalimumab (Humira) and etanercept (Enbrel) OR documentation demonstrating that a trial may be inappropriate. For Giant Cell Arteritis: documentation of inadequate response/inability to tolerate oral corticosteroids

ACTHAR HP

Products Affected

- ACTHAR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins or porcine origin, or where congenital infections are suspected in infants. OR Administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of H.P. Acthar Gel. Concurrent primary adrenocortical insufficiency or adrenocortical hyperfunction.
Required Medical Information	
Age Restrictions	For diagnosis of IS: 2 years of age and younger, for diagnosis of MS: 18 years of age and older, for all other indications: 2 years of age and older
Prescriber Restrictions	Infantile spasms: pediatric neurologist or neonatologist, all other indications: neurologist, rheumatologist, nephrologist, pulmonologist, or ophthalmologist
Coverage Duration	Infantile Spasms=1 yr All Other=1 month
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when ONE of the following is present: infantile spasms OR there has been inadequate response or inability to tolerate systemic steroids (eg prednisone, methylprednisolone) and ONE of the following (1) acute exacerbation of multiple sclerosis currently receiving maintenance treatment for MS (eg Avonex, Betaseron, Copaxone, Tecfidera, etc) (2) acute exacerbation of psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis or ankylosing spondylitis currently receiving DMARD (3) nephrotic syndrome and ALL of the following (a) proteinuria greater than3.5g/ 24 hours AND (b) serum albumin less than 3 mg/dL AND (c) peripheral edema (4) systemic lupus erythematosus, systemic dermatomyositis, severe erythema multiforme, Stevens-Johnson syndrome, serum sickness, inflammatory ophthalmic disease, or symptomatic sarcoidosis

ACUTE HAE AGENTS

Products Affected

- BERINERT
- FIRAZYR
- *icatibant acetate*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an allergist or immunologist
Coverage Duration	Lifetime
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when the following inclusion criterion is met: documentation of treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE)

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy
Required Medical Information	
Age Restrictions	Deny if age is less than 18 years
Prescriber Restrictions	
Coverage Duration	6 month for initial authorization and 12 months for renewal authorizations
Other Criteria	Documentation of ONE of the following: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II - IV AND (a) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (b) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, OR (2) Diagnosis of persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH. Re-authorization: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

AMPYRA

Products Affected

- AMPYRA
- *dalfampridine er*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if patient has history of seizure or moderate to severe renal impairment (CrCL = 50 mL/min)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Diagnosis of multiple sclerosis REAUTHORIZATION CRITERIA: documentation of improvement in walking speed

ANADROL

Products Affected

- ANADROL-50

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Acquired aplastic anemia (2) Anemia of chronic renal failure (3) Antineoplastic adverse reaction - Myelosuppression (4) Fanconi's anemia (5) Pure red cell aplasia OR (6) Cachexia associated with AIDS

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Deny if not prescribed by a pulmonologist or an infectious diseases specialist
Coverage Duration	Indefinite
Other Criteria	Both of the following: (1) Member has not achieved negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen therapy and (2) documentation that the medication will be used as part of a combination antibacterial regimen

ARMODAFINIL/MODAFINIL

Products Affected

- *armodafinil*
- *modafinil*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	For NARCOLEPSY or SHIFT WORK DISORDER: Recommended by a neurologist or sleep specialist
Coverage Duration	Indefinite
Other Criteria	FOR NARCOLEPSY: Documentation of a diagnosis of Narcolepsy. FOR OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): Documentation that the medication is being used as an adjunct treatment for the underlying obstruction. FOR SHIFT WORK SLEEP DISORDER (SWSD): Documentation that the member has no medical or mental disorder accounting for the symptoms AND the symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g. time-zone change [jet lag] syndrome)

BENLYSTA SC

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following are met: (1) documentation of active, autoantibody-positive, systemic lupus erythematosus (SLE) AND (2) patient is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressives, nonsteroidal anti-inflammatory drugs (NSAIDS)

BRAND ORAL FENTANYL

Products Affected

- ABSTRAL
- *fentanyl citrate buccal*
- FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- SUBSYS SUBLINGUAL LIQUID 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ALL of the following: (1) pain associated with cancer, (2) long-acting pain medication regimen, (3) member is opioid tolerant as demonstrated by adherence for one week or more of any of the following regimens: at least 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid AND (4) inadequate response to a generic oral transmucosal fentanyl citrate product

CARBAGLU

Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS)

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 7 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of all of the following: (1) cystic fibrosis, (2) Pseudomonas Aeruginosa in the lungs, (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam AND (4) FEV1 between 25% and 75% of predicted

CERDELGA

Products Affected

- CERDELGA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Patient is CYP2D6 Ultra Rapid Metabolizer (URM), concurrent use of Class 1A or Class III anti-arrhythmic, long QT syndrome, patient has pre-existing cardiac disease
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of Type 1 Gaucher disease and patient is CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) as detected by an FDA-cleared test for determining CYP2D6 genotype

CGRP ANTAGONISTS

Products Affected

- AIMOVIG
- AJOVY
- EMGALITY

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties
Coverage Duration	6 months for initial authorization, 12 months for reauthorization
Other Criteria	Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate ONE of the following (a) a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine OR (b) Inadequate response or inability to tolerate onabotulinumtoxin A (Botox) REAUTHORIZATION criteria: BOTH of the following: (1) Prescribed by or in consultation with a neurologist or headache specialist (2) Documentation of response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity)

CHOLBAM

Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if there is documentation of extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorder
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial criteria: 3 months. Re-authorization criteria: indefinite
Other Criteria	Documentation of One of the following: (a) Treatment of bile acid synthesis disorder due to single enzyme defect (b) Adjunctive treatment of peroxisomal disorder including Zellweger spectrum disorder in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption. Re-authorization criteria: Documentation of improved liver function tests from the start of treatment.

CIALIS

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of BPH and an inadequate response or inability to tolerate an alpha blocker (e.g. terazosin)

CIMZIA

Products Affected

- CIMZIA PREFILLED
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	CD: Prescribed by a gastroenterologist. RA, AS, nr-axSpA: Prescribed by a rheumatologist. PsA: prescribed by a dermatologist or rheumatologist. Plaque psoriasis: Prescribed by a dermatologist.
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) for diagnosis of Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, or Rheumatoid Arthritis: inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate (2) for diagnosis of Crohn's Disease: inadequate response or inability to tolerate adalimumab (Humira), or documentation demonstrating that a trial may be inappropriate, (3) Diagnosis of Non-radiographic axial Spondyloarthritis AND inadequate response or inability to tolerate two NSAIDs

CINRYZE

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	Deny if not prescribed by an allergist or immunologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when ALL of the following criteria are met: (1) Diagnosis of hereditary angioedema (HAE) (2) history of laryngeal edema or airway compromise with an episode of HAE or a history of at least 2 HAE attacks per month, AND (3) inadequate response or inability to tolerate 17 alpha-alkylated androgens (e.g. danazol, oxandrolone, stanozolol) or anti-fibrinolytic agents (e.g. epsilon aminocaproic acid, tranexamic acid) for HAE prophylaxis

CORLANOR

Products Affected

- CORLANOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Chronic Heart Failure: (1)Diagnosis of chronic heart failure. (2) stable, symptomatic chronic heart failure (3) left ventricular ejection fraction less than or equal to 35% and (4) sinus rhythm with resting heart rate greater than or equal to 70 beats per minute.Chronic Heart Failure due to Dilated Cardiomyopathy: (1) Diagnosis of chronic heart failure due to dilated cardiomyopathy (2) Patient is in sinus rhythm.
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	Indefinite
Other Criteria	Patient is clinically stable for at least 4 weeks on an optimized and stable clinical regimen which includes: (a) maximally tolerated doses of beta blockers or inability to tolerate beta blockers, (b) ACE inhibitors or ARBs or inability to tolerate ACE inhibitor or ARB

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist or dermatologist.
Coverage Duration	Indefinite
Other Criteria	Diagnosis of plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis and inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

CRESEMBA [ORAL]

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	prescribed by or in consultation with an infectious disease specialist
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of either of the following (1) for use in the treatment of invasive aspergillosis after inadequate response or inability to tolerate Voriconazole (Vfend) OR for a diagnosis of mucormycosis

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of cystinosis AND (2) patient has corneal cystine crystal accumulation

DEFERASIROX

Products Affected

- *deferasirox*
- EXJADE
- JADENU
- JADENU SPRINKLE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	CrCl less than 40 mL/min or serum creatinine more than 2 times the age-appropriate ULN, platelet counts less than 50,000/mL
Required Medical Information	Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months)
Age Restrictions	Deny if than 2 years
Prescriber Restrictions	
Coverage Duration	Initial approval=3 months, Reauthorization=6 months
Other Criteria	Documentation of ONE of the following diagnoses: (1) Chronic iron overload in nontransfusion-dependent thalassemia syndromes and all of the following: (a) patient 10 years and older (b) liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw) and (c) serum ferritin greater than 300 mcg/L OR (2) For the treatment of chronic iron overload caused by blood transfusions (transfusional hemosiderosis) in patients 2 years and older Reauthorization criteria: One of the following: (1) Documentation of a decreased serum ferritin level compared with the baseline level for transfusion- dependent anemia or (2) Documentation of a decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration) for Non-transfusion dependent thalassemia syndrome

DICLOFENAC 3% PRODUCTS

Products Affected

- *diclofenac sodium transdermal gel 3 %*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	90 days
Other Criteria	Documentation of diagnosis of Actinic Keratoses

DIFICID

Products Affected

- DIFICID

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	10 days
Other Criteria	Documentation of the presence of Clostridium difficile-associated diarrhea confirmed by laboratory testing AND documentation of inadequate response or inability to tolerate metronidazole OR vancomycin RE-AUTHORIZATION CRITERIA: documentation of consultation with an infectious disease specialist

DOPTELET

Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation of baseline platelet count less than 50,000/mcL
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Chronic Liver Disease: 1 month Chronic Immune Thrombocytopenia: Initial 6 months, Reauth 12 months
Other Criteria	(For Chronic ITP only): Both of the following are met: (1) Diagnosis of Chronic Immune Thrombocytopenia (Chronic ITP), (2) Inadequate response or inability to tolerate previous treatment. Reauthorization criteria (diagnosis of Chronic ITP only): Documentation of positive clinical response.

DUPIXENT

Products Affected

- DUPIXENT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 12 years old.
Prescriber Restrictions	Deny if prescriber is not a dermatologist, allergist, immunologist, ENT specialist or pulmonologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (A) Diagnosis of atopic dermatitis BOTH of the following: (1) diagnosis or moderate-severe atopic dermatitis AND (2) inadequate response or inability to tolerate BOTH of the following (a) one topical steroid (medium potency or higher) AND (b) topical tacrolimus. (B) Diagnosis of asthma documentation is provided of both of the following: (1) ONE of the following: (a) Member has oral corticosteroid-dependent asthma or (b) Member has blood eosinophil levels of at least 150 cells/mcL at baseline or at least 300 cells/mcL within the past 12 months AND (2) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication, (C) Diagnosis of chronic rhinosinusitis with nasal polyposis and an Inadequate response or inabilty to tolerate ONE intranasal corticosteroid

EGRIFTA

Products Affected

- EGRIFTA SUBCUTANEOUS SOLUTION RECONSTITUTED 1 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	(1) hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, or head irradiation or trauma, (2)hypersensitivity to tesamorelin and/or mannitol, (3)malignancy, active (either newly diagnosed or recurrent) malignancies should be inactive and completely treated prior to initiating therapy, (4)pregnancy.
Required Medical Information	Waist hip ratio and waist circumference
Age Restrictions	
Prescriber Restrictions	Deny if prescriber is not a HIV-infection specialist
Coverage Duration	Remainder of contract year
Other Criteria	Patient is receiving antiretroviral therapy (ART) AND Revision of the ART regimen have been ineffective in reducing the excess VAT

EMFLAZA

Products Affected

- EMFLAZA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 5 years of age
Prescriber Restrictions	Deny if not prescribed by a neurologist
Coverage Duration	Indefinite
Other Criteria	Inadequate response or inability to tolerate prednisone

EMGALITY-CLUSTER HEADACHES

Products Affected

- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, pain specialist.
Coverage Duration	3 months for initial, 12 months for reauthorization.

PA Criteria	Criteria Details
Other Criteria	Episodic cluster headache (ECH) (initial) : Diagnosis of ECH. Member has experienced at least 2 cluster periods lasting 6 days to 365 days, separated by pain-free periods lasting at least three months. Emgality 100mg/ml will not be used in combination with another CGRP inhibitor. Prescribed by or in consultation with a neurologist, headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist. Episodic migraines (EM) (initial): Diagnosis of EM defined as 4 to 14 headache days per month. Inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications: (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine. Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties. Chronic migraines (CM)(initial) : Diagnosis of CM defined as greater than or equal to 15 headache days per month. Inadequate response or inability to tolerate ONE of the following: (a) a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine OR (b) Inadequate response or inability to tolerate onabotulinumtoxin A (Botox). Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties REAUTHORIZATION criteria: (ECH) (reauth): Prescribed by or in consultation with a neurologist or headache specialist or pain specialist. Documentation of response to therapy as defined by a reduction in weekly cluster headache attacks.(EM, CM) (reauth): Prescribed by or in consultation with a neurologist or headache specialist. Documentation of response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity).

EMSAM

Products Affected

- EMSAM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation that at least 14 days has elapsed after discontinuation of antidepressants without long half-lives OR documentation at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives e.g. Fluoxetine.
Age Restrictions	Deny in patients less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of diagnosis of major depressive disorder AND a documented inadequate response or inability to tolerate ONE SSRI or SNRI

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if patient is less than 2 years
Prescriber Restrictions	Deny if not prescribed by Rheumatologist or Dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of a previous trial with infliximab (Remicade) OR ONE of the following: (1) For moderate to severe Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis or Juvenile Idiopathic Arthritis: Inadequate response or inability to tolerate ONE of the following: methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine OR (2) For moderate to severe Plaque Psoriasis: inadequate response or inability to tolerate ONE of the following drugs: Topical Calcipotriene, Topical Anthralin, Topical Steroids, Topical immunomodulators (Elidel, Protopic), Topical retinoids.

ENDARI

Products Affected

- ENDARI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by a hematologist or oncologist
Coverage Duration	Indefinite
Other Criteria	Member has had 2 or more painful sickle cell crises within the past 12 months

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	baseline CBC, serum transaminases and total bilirubin prior to initiating therapy
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Dravet Syndrome: Approved when BOTH of the following inclusion criteria is met: (1) Documentation of an inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid (c) levetiracetam (d) topiramate and (2) Documentation of concurrent use with additional anti-epileptic(s) Lennox-Gastaut Syndrome: Approved when BOTH of the following inclusion criteria is met: (1) Documentation of an inadequate response or inability to tolerate ONE of the following (a) valproic acid (b) lamotrigine (c) topiramate (d)felbamate (e)rufinamide (f) clobazam and (2) Documentation of concurrent use with additional anti-epileptic(s)

EUCRISA

Products Affected

- EUCRISA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of inadequate response or inability to tolerate at least one of the following: (a) generic topical tacrolimus, OR (b) generic, prescription medium potency or higher topical steroid.

EVEKEO

Products Affected

- *amphetamine sulfate*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	For ADHD: deny if less than 3 years old, For Narcolepsy: deny if less than 6 years old
Prescriber Restrictions	
Coverage Duration	Remainder of Contract Year
Other Criteria	

EVENITY

Products Affected

- EVENITY

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Osteoporosis defined as T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR history of osteoporotic fracture (i.e. hip, spine, etc.)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Member has had an inadequate response or inability to tolerate BOTH of the following: (a) at least one of the following (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs), AND (b) Denosumab (Prolia). Documentation that cumulative lifetime therapy does not exceed 12 months.

FASENRA

Products Affected

- FASENRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if patient is less than 12 years of age
Prescriber Restrictions	Prescribed by or in consultation with pulmonologist or allergy/immunology specialist
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following: 1) Diagnosis of severe asthma with eosinophilic phenotype as defined by ONE of the following at initiation of therapy (a) blood eosinophil levels are at least 150 cells/microliter if dependent on daily oral corticosteroids for at least 6 continuous months or (b) blood eosinophil levels are at least 300 cells/microliter AND 2) ONE of the following: a) Patient has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or b) Any prior intubation for asthma exacerbation, or c) prior asthma-related hospitalization within the past 12 months, AND 3) Patient is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: a) high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR b) one maximally-dosed combination ICS/LABA product)

FENTANYL CITRATE LOZENGE

Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 16 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of all of the following: (1) pain associated with cancer, (2) long acting medication regimen AND (3) member is opioid tolerant as demonstrated by adherence to one of the following regimens for at least one week: at least 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid

FERRIPROX

Products Affected

- FERRIPROX ORAL SOLUTION
- FERRIPROX ORAL TABLET 500 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of both of the following inclusion criteria: transfusional iron overload due to thalassemia syndromes AND inadequate response or inability to tolerate current chelation therapy

FIRDAPSE

Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	History of seizures
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Deny if not prescribed by or in consultation with a neurologist.
Coverage Duration	90 Days, indefinite for continuation
Other Criteria	INITIAL CRITERIA: Both of the following: (1) Neurological symptoms persist after treatment of malignancy, when malignancy is present and (2) Documentation the member has moderate to severe weakness that interferes with function. CONTINUATION CRITERIA: Documentation is provided of a positive clinical response to therapy

FLECTOR

Products Affected

- *diclofenac epolamine*
- FLECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Required Medical Information	Patient had experienced treatment failure with at least 2 prescription strength oral NSAIDs or patient has a documented swallowing disorder OR has a history of peptic ulcer disease/gastrointestinal bleeding OR patient is more than 65 years of age with one additional risk factor for gastrointestinal adverse event (e.g., use of anticoagulants or chronic corticosteroids)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	

FORTEO

Products Affected

- FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML
- TYMLOS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Any of the following: (1) history of Paget's disease of the bone (2) history of bone cancer or other cancers that have metastasized to the bone (3) Skeletal malignancies or other metabolic bone disease besides osteoporosis (4) Preexisting hypercalcemia (5) Pregnant or nursing women (6) unexplained elevations of alkaline phosphatase (7) open epiphyses (8) history of external beam or implant radiation therapy involving the skeleton
Required Medical Information	Osteoporosis defined as T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR history of osteoporotic fracture (i.e. hip, spine, etc.). Glucocorticoid induced osteoporosis in men or women defined as daily dose greater than or equal to 5mg prednisone or equivalent for at least 3 months
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	(1) Diagnosis of Primary or hypogonadal osteoporosis in men OR diagnosis of Glucocorticoid- induced osteoporosis in men or women, member has had an Inadequate response or inability to tolerate at least one of the following (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs). (2) Diagnosis of postmenopausal osteoporosis, member has had an Inadequate response or inability to tolerate BOTH of the following: (a) at least one of the following (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs), AND (b) Denosumab (Prolia). Reauthorization criteria: documentation that cumulative lifetime therapy does not exceed 2 years

GALAFOLD

Products Affected

- GALAFOLD

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation that member has amenable galactosidase alpha gene (GLA) variant per FDA labeling information
Age Restrictions	Deny if less than 16 years of age
Prescriber Restrictions	Deny if not prescribed by or in consultation with a clinical genetics specialist
Coverage Duration	Initial: 6 months, reauthorization: indefinite
Other Criteria	REAUTHORIZATION: documentation of response to therapy

GATTEX

Products Affected

- GATTEX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Documentation of ALL of the following: (1) diagnosis of Short Bowel Syndrome AND (2) individual receives parenteral support at least three times per week. REAUTH CRITERIA: Reduction in parenteral support from baseline (prior to initiation of Gattex therapy)

GROWTH HORMONES

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK
- HUMATROPE
- NORDITROPIN FLEXPRO
- NUTROPIN AQ NUSPIN 10
- NUTROPIN AQ NUSPIN 20
- NUTROPIN AQ NUSPIN 5
- OMNITROPE
- SAIZEN
- SAIZENPREP
- ZOMACTON

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	(1) Growth failure in children when all of the following inclusion criteria are met: (a) subnormal serum insulin-like growth factor-1 (IGF-1), (b) growth velocity less than or equal to 5 cm/year after 2 years of age, (c) documentation of bone age and (d) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levadopa, or clonidine. (2) Small for gestational age (SGA) with clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth failure associated with chronic kidney disease (CKD), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency, (5) Diagnostically confirmed Growth hormone deficiency in adults OR (6) Idiopathic short stature defined by height standard deviation score (SDS) less than or equal to 2.25 and documentation of growth velocity
Age Restrictions	
Prescriber Restrictions	Recommendation by an endocrinologist or nephrologist
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	CONTINUATION OF GROWTH HORMONE: for additional 12 months: Annual clinical re-evaluation by the treating endocrinologist AND one of the following criteria is met: (1) for Growth failure in children - normalization of IGF-1 (2) for Small for gestational age (SGA) - increase in growth velocity from baseline (3) for Growth failure associated with chronic kidney disease (CKD) - no history of renal transplant (4) for Growth failure associated with Noonan Syndrome, Prader-Willi, Turner Syndrome OR SHOX - documentation of clinical reevaluation by endocrinologist (5) for Growth hormone deficiency in adults - normalization of IGF-1: OR (6) Idiopathic short stature - increase in growth velocity from baseline

HAEGARDA

Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an allergist or immunologist
Coverage Duration	Indefinite
Other Criteria	ALL of the following criteria are met: (1) Diagnosis of hereditary angioedema (HAE) (2) history of laryngeal edema or airway compromise with an episode of HAE or a history of at least 2 HAE attacks per month, AND (3) inadequate response or inability to tolerate 17 alpha-alkylated androgens (e.g. danazol, oxandrolone, stanozolol) or anti-fibrinolytic agents (e.g. epsilon aminocaproic acid, tranexamic acid) for HAE prophylaxis

HETLIOZ

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by a sleep specialist or neurologist
Coverage Duration	Remainder of contract year
Other Criteria	Diagnosis of a circadian period greater than 24 hours

HIGH DOSE OPIOIDS

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr*
- *hydromorphone hcl er*
- *hydromorphone hcl oral tablet 4 mg, 8 mg*
- *methadone hcl oral solution*
- *methadone hcl oral tablet*
- *morphine sulfate er beads oral capsule extended release 24 hour 120 mg*
- *morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg*
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 30 mg, 60 mg, 80 mg*
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 40 mg*
- *oxycodone hcl oral tablet 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 40 mg*
- *oxymorphone hcl oral tablet 10 mg*
- XTAMPZA ER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	NEW TO HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (A) pain associated with cancer OR (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy. CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (c) member has improved functioning AND (d) member is not being treated for substance abuse

HOMOZYGOUS FAMILIAL HYPERCHOLESEROLEMIA AGENTS

Products Affected

- JUXTAPID

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Kynamro and Jutaxapid: Moderate-severe liver impairment, active liver disease, unexplained LFT abnormalities. Juxtapid: Pregnancy, concomitant use with strong or moderate CYP3A4 inhibitors.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of Homozygous Familial Hypercholesterolemia with ONE of the following: (a) Genetic confirmation of 2 mutant alleles at the LDL receptor. Apo B, PCSK9, or ARH adaptor protein gene locus (b) Untreated LDL-C greater than 500 mg/dL or treated LDL cholesterol greater than or equal to 300 mg/dL or treated non-HDL cholesterol greater than or equal to 330 mg/dL together with either of the following: (i) Cutaneous or tendonous xanthoma prior to 10 years of age (ii) Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents AND (2) Inadequate response or inability to tolerate the combination of ONE high potency statin at the maximally tolerated dose (e.g., atorvastatin, rosuvastatin) with either ezetimibe or a Bile Acid Sequestrant (e.g. cholestyramine). REAUTHORIZATION CRITERIA: Documentation of reduction in LDL level since initiation of therapy with respective drug

HRM

Products Affected

- *benztropine mesylate oral*
- *butalbital-acetaminophen*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-aspirin-caffeine oral capsule*
- *chlorzoxazone oral tablet 375 mg, 750 mg*
- *dicyclomine hcl oral*
- DIGITEK ORAL TABLET 250 MCG
- DIGOX ORAL TABLET 250 MCG
- *digoxin oral tablet 250 mcg*
- *dipyridamole oral*
- *ergoloid mesylates oral*
- *hydroxyzine hcl oral tablet*
- INDOCIN ORAL
- *indomethacin er*
- *indomethacin oral*
- *methocarbamol oral*
- PHENADOZ RECTAL SUPPOSITORY 12.5 MG
- PHRENILIN FORTE ORAL CAPSULE 50-300-40 MG
- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG
- TENCON ORAL TABLET 50-325 MG
- *trihexyphenidyl hcl*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM ESTROGENS

Products Affected

- AMABELZ
- BIJUVA
- CLIMARA PRO
- COMBIPATCH
- DIVIGEL TRANSDERMAL GEL 1 MG/GM
- DOTTI
- *estradiol oral*
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- FYAVOLV
- JINTELI
- LOPREEZA ORAL TABLET 1-0.5 MG
- MENOSTAR
- MIMVEY
- MIMVEY LO
- *norethindrone-eth estradiol*
- PREFEST
- PREMARIN ORAL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets, rings, or cream, etc) OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM LONG ACTING SULFONYLUREAS

Products Affected

- *glyburide micronized*
- *glyburide oral*
- *glyburide-metformin*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate glipizide and glimepiride OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM NON BENZODIAZEPINE HYPNOTICS

Products Affected

- *eszopiclone*
- *zaleplon*
- *zolpidem tartrate er*
- *zolpidem tartrate oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	3 months for initial authorization, end of contract year for reauthorization
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate ramelteon (Rozerem) OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly REAUTHORIZATION CRITERIA: documentation that prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days)

HRM SHORT TERM SKELETAL MUSCLE RELAXANTS

Products Affected

- *carisoprodol oral*
- *carisoprodol-aspirin*
- *carisoprodol-aspirin-codeine*
- *cyclobenzaprine hcl er*
- *cyclobenzaprine hcl oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Acute muscle spasms= 3 weeks, all other indications= end of coverage year
Other Criteria	Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in the elderly

HRM TCAS

Products Affected

- *amitriptyline hcl oral*
- *clomipramine hcl oral*
- *doxepin hcl oral*
- *imipramine hcl oral*
- *imipramine pamoate*
- *nortriptyline hcl oral*
- *perphenazine-amitriptyline*
- *trimipramine maleate oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate one generic SSRI (e.g. sertraline, fluoxetine, etc) or one generic SNRI (e.g. duloxetine, venlafaxine) OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HUMIRA

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML, 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PS/UV/ADOL HS START
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 2 years for JIA or Uveitis, less than 6 years for Crohn's disease, less than 12 years for hidradenitis suppurativa, less than 18 years for all other indications
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist, Dermatologist, Ophthalmologist or Gastroenterologist accordingly
Coverage Duration	Indefinite
Other Criteria	Documentation of a previous trial with infliximab (Remicade) OR ONE of the following: (1) For moderate to severe Rheumatoid Arthritis, Ankylosing Spondylitis, moderate to severe Juvenile Idiopathic Arthritis (JIA) , or Psoriatic Arthritis: inadequate response or inability to tolerate ONE of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine, (2) For moderate to severe Plaque Psoriasis: inadequate response or inability to tolerate ONE of the following drugs: topical calcipotriene containing products, topical anthralin, topical steroids, topical immunomodulators (Elidel, Protopic), topical retinoids (3) For Crohn's Disease or Ulcerative Colitis: inadequate response or inability to tolerate ONE of the following: corticosteroid, Aminosalicylate, or Immunomodulators (ex. azathioprine or 6-mercaptopurine), (4) diagnosis of Hidradenitis suppurativa OR (5) diagnosis of non-infectious intermediate, posterior, or pan- uveitis and inadequate response or inability to tolerate BOTH of the following (1) ONE topical ophthalmic steroid AND (2) ONE oral corticosteroid

ILUMYA

Products Affected

- ILUMYA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to the start of therapy
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of the following: plaque psoriasis and inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

INBRIJA

Products Affected

- INBRIJA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	Documentation is provided of ALL of the following: (1) Member is receiving Inbrija in combination with carbidopa/levodopa containing product, (2) Member is experiencing intermittent OFF episodes, (3) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g., rasagiline, selegiline), (b) Dopamine agonist (e.g., pramipexole, ropinirole), (c) COMT inhibitor (e.g., entacapone)

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Known or suspected malignancy, closed epiphyses, concurrent GH therapy
Required Medical Information	
Age Restrictions	Deny if less than 2 years
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Diagnosis of ONE of the following: (1) growth hormone gene deletion who have developed neutralizing antibodies to growth hormone OR (2) Severe primary IGF-1 deficiency and ALL of the following (a) height standard deviation score less than or equal to -3.0 AND (b) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone CONTINUATION OF INCRELEX: documentation of increase in growth velocity from baseline AND annual clinical re-evaluation by the treating endocrinologist

INGREZZA

Products Affected

- INGREZZA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a psychiatrist
Coverage Duration	Initial authorization: 3 months, Reauthorization: indefinite
Other Criteria	ALL of the following (1) Diagnosis of moderate to severe tardive dyskinesia (2) documentation of baseline AIMS and (3) one of the following: (a) persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication, or (b) member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Reauthorization criteria: Valbenazine (Ingrezza) is reapproved with documentation of positive clinical response, as demonstrated by improvement in AIMS, to Ingrezza therapy

INHALED TOBRAMYCIN

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	6 years of age or older
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(1) diagnosis of cystic fibrosis AND (2) evidence of P. aeruginosa in the lungs

INJECTABLE METHOTREXATE

Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML
- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Psoriasis: deny if less than 18 years
Prescriber Restrictions	RA and pJIA: Recommended by rheumatologist. Psoriasis: recommended by dermatologist
Coverage Duration	Indefinite
Other Criteria	Injectable Methotrexate is approved when ONE of the following is met: (1) Diagnosis of severe, active rheumatoid arthritis (RA), psoriatic arthritis or polyarticular juvenile idiopathic arthritis (pJIA) and inadequate response or inability to tolerate oral methotrexate OR (2) diagnosis of severe psoriasis and an inadequate response to BOTH of the following (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.)

INTRAVENOUS IMMUNE GLOBULIN (IVIG)

Products Affected

- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PANZYGA
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	primary immune deficiency disease(eg congenital hypogammaglobulinemia, immunodeficiency with increased IGM, common variable immunodeficiency Wiskott-Aldrich Syndrome, combined immunity deficiency)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when ONE of the following is present (1) autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid , benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (ie steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (ie steroids, immunosuppressants) (2) Erythema multiforme major (SJS, TEN) and SCORTEN level 3 or greater (3) scleromyxedema (4) acute idiopathic thrombocytopenia purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures) (c) severe thrombocytopenia (platelets less than 20, 000 per uL) or (d) high risk for intracerebral hemorrhage (5) chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL (6) chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy (7) hematopoetic stem cell transplant and IgG less than 400mg/dL (8) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis (9) solid organ transplant (10) chronic inflammatory demyelinating polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids (11) dermatomyositis or polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants (12) Guillain Barre syndrome with impaired function (ie unable to stand or walk without aid) (13) Lambert Eaton myasthenic syndrome refractory to steroids, immunosuppressants, or cholinesterase inhibitors (14) multifocal motor neuropathy diagnosed by electrodiagnostic studies (15) acute exacerbations of MS unresponsive to steroids (16) myasthenia gravis refractory to at least 8 weeks of standard therapy (steroids, immunosupressants, cholinesterase inhibitors) (17) myasthenic crisis (18) stiff person syndrome refractory to standard therapy (muscle relaxants, benzodiazepines, gabapentin) (19)
	severe, active SLE unresponsive to steroids (20) Kawasaki disease CONTINUATION OF THERAPY CRITERIA: Documentation of clinical improvement as appropriate to the diagnosis such as, but not limited to, Rankin score and Activities of Daily Living (ADL) scores.

JYNARQUE

Products Affected

- JYNARQUE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Baseline serum transaminases and bilirubin prior to initiation of therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Deny if not prescribed by a nephrologist or kidney transplant specialist
Coverage Duration	3 months for initial and 12 months for re-authorization
Other Criteria	RE-AUTHORIZATION: ALL of the following (1) ONE of the following (a) decline in kidney function has slowed or (b) kidney pain has improved and (2) serum transaminase less than 3 times the upper limit of normal and (3) bilirubin less than 2 times upper limit of normal

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Mutation was documented by an FDA-cleared CF to detect the presence of the CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions
Age Restrictions	Deny if age less than 6 months for granules and less than 6 years of age for tablets
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of Cystic Fibrosis with documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data

KEVEYIS

Products Affected

- KEVEYIS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concomittant use of high dose Aspirin, severe pulmonary disease and hepatic insufficiency
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by or in consultation with a neurologist
Coverage Duration	Initial criteria: 3 months Reauthorization: indefinite
Other Criteria	Reauthorization Criteria: Dichlorphenamide (Keveyis) is reapproved with documentation that prescriber has evaluated the patient's response to dichlorphenamide and recommends continuation of the treatment

KEVZARA

Products Affected

- KEVZARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to start of therapy
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by rheumatologist
Coverage Duration	Indefinite
Other Criteria	Rheumatoid arthritis: BOTH of the following (1) inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

KINERET

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by rheumatologist or pediatric specialist
Coverage Duration	Indefinite
Other Criteria	For diagnosis of Rheumatoid Arthritis or Juvenile idiopathic arthritis: inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel)

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by or in consultation with an endocrinologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following: (1) hyperglycemia secondary to hypercortisolism in adult patient with endogenous Cushing syndrome, (2) patient has type 2 diabetes mellitus or glucose intolerance AND (3) patient has failed surgery or is not a candidate for surgery.

LIDOCAINE TRANSDERMAL PATCH

Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of post-herpetic neuralgia or diabetic peripheral neuropathy

MULPLETA

Products Affected

- MULPLETA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation of baseline platelet count less than 50,000/mcL
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	

MYALEPT

Products Affected

- MYALEPT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by or in consultation with an endocrinologist
Coverage Duration	Indefinite
Other Criteria	All of the following: (1) Diagnosis of congenital or acquired generalized lipodystrophy and (2) patient is refractory to both of the following current standards of care: (a) Lipid management, (b) diabetic management and (3) One or moreof the following metabolic abnormalities are present: (a) Insulin resistance (defined as requiring more than 200 units per day), (b) Hypertriglyceridemia, (c) Diabetes

NATPARA

Products Affected

- NATPARA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if patient has a diagnosis of hypoparathyroidism caused by calcium-sensing receptor mutations or post-surgical hypoparathyroidism
Required Medical Information	
Age Restrictions	Deny if age less than 18 years
Prescriber Restrictions	Deny if not prescribed by or in consultation with an endocrinologist
Coverage Duration	Initial authorization: 6 month, Re-authorization: until the end of the contract year
Other Criteria	Documentation of the following: Diagnosis of hypoparathyroidism.

NON ORAL PAH AGENTS

Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 months for initial approvals and 12 months for Continuation approvals
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when ALL of the following are met: (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. CONTINUATION OF THERAPY: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

NON-ORAL ANTIBIOTICS

Products Affected

- AVYCAZ
- DALVANCE
- *daptomycin*
- *linezolid intravenous solution 600 mg/300ml*
- NUZYRA INTRAVENOUS
- SIVEXTRO
- TEFLARO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an infectious disease (ID) specialist or prescribed with ID consultation (telephone consultation is acceptable) including name of the ID specialist and date of the consultation within the last 60 days
Coverage Duration	1 month
Other Criteria	Subject to Part B vs Part D review. and if Part D is medically necessary when documentation of a current bacterial infection and an inadequate response or inability to tolerate at least TWO drugs to which the organism is susceptible OR the requested agent is the only antibiotic to which the organism is susceptible. RE-AUTHORIZATION CRITERIA: Documentation that an infectious disease consult determines that a longer duration of therapy is required.

NON-ORAL CHEMO AGENTS

Products Affected

- SYNRIBO
- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) Documentation of continuous therapy with the medication requested

NON-PREFERRED HEPATITIS C AGENTS

Products Affected

- SOVALDI
- VIEKIRA PAK
- VOSEVI
- ZEPATIER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Hepatitis C Genotype
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	BOTH of the following (1) criteria will be applied consistent with current AASLD/ IDSA guidance and (2) inability to tolerate Harvoni or Epclusa or Mavyret where indicated

NOXAFIL

Products Affected

- NOXAFIL ORAL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 13 years
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of either of the following (1) for use in prophylaxis of invasive Aspergillus and Candida infections due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend) OR (2) for a diagnosis of oropharyngeal candidiasis after inadequate response or inability to tolerate both itraconazole and fluconazole

NUCALA

Products Affected

- NUCALA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if patient is less than 12 years of age
Prescriber Restrictions	Prescribed by or in consultation with pulmonologist or allergy/immunology specialist
Coverage Duration	12 months for Initial and Re-authorization criteria

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when there is documentation of ONE of the following: 1) Diagnosis of severe asthma with eosinophillic phenotype as defined by one of the following: 1) blood eosiniophil levels are at least 150 cells/microliter at initiation of therapy, or 2) blood eosinophil levels at least 300 cells/microliter within the past 12 months, and 2) Patient is currently treated with high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g., long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents, OR II) Diagnosis of Eosinophilic Granulomatosis with Polyangitis (EGPA) and ALL of the following: (1) Member's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy), and (2) Member is currently receiving corticosteroid therapy (e.g., prednisolone, prednisone). Reauthorization criteria: For Diagnosis of severe asthma: Patient is currently treated with high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 880mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g., long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. For Diagnosis of EGPA: Documentation of positive clinical response to therapy (e.g., increase in remission time)

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of Pseudobulbar affect

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of inadequate response or inability to tolerate ONE of the following (1) quetiapine or (2) clozapine.

OCALIVA

Products Affected

- OCALIVA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with hepatologist or gastroenterologist
Coverage Duration	Initial authorization is 6 months and Reauthorization=Indefinite
Other Criteria	Approved when One of the following is met: (1) Used in combination with ursodeoxycholic acid and patient had suboptimal response to at least 12 consecutive months of treatment with ursodeoxycholic acid (e.g., Urso, Urso Forte, ursodiol), OR (2) inability to tolerate ursodeoxycholic acid . Reauthorization is approved with documentation of positive clinical response to Ocaliva therapy

OLUMIANT

Products Affected

- OLUMIANT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Recommended by a rheumatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) inadequate response or inability to tolerate adalimumab (Humira) AND etanercept (Enbrel) or (2) documentation demonstrating that a trial may be inappropriate

ORAL ANTIBIOTICS

Products Affected

- *linezolid oral*
- NUZYRA ORAL TABLET 150 MG
- SIVEXTRO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an infectious disease (ID) specialist or prescribed with ID consultation (telephone consultation is acceptable) including name of the ID specialist and date of the consultation within the last 60 days
Coverage Duration	1 month
Other Criteria	Documentation of a current bacterial infection and an inadequate response or inability to tolerate TWO antibiotics to which the organism is susceptible OR the requested medication is the only antibiotic to which the organism is susceptible. RE-AUTHORIZATION CRITERIA: Documentation that an infectious disease consult determines that a longer duration of therapy is required.

ORAL CHEMO AGENTS

Products Affected

- *abiraterone acetate*
- AFINITOR
- AFINITOR DISPERZ
- ALECENSA
- ALUNBRIG
- BALVERSA
- *bexarotene*
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- CABOMETYX
- CALQUENCE
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE)
- COMETRIQ (140 MG DAILY DOSE)
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- FARYDAK
- GILOTRIF
- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA
- INLYTA
- INREBIC
- IRESSA
- JAKAFI
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KISQALI FEMARA(200 MG DOSE)
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LYNPARZA ORAL TABLET
- MEKINIST
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- REVLIMID
- RUBRACA
- RYDAPT
- SPRYCEL
- STIVARGA
- SUTENT
- TAFINLAR
- TAGRISSO
- TALZENNA
- TARCEVA
- TASIGNA
- THALOMID
- TIBSOVO
- TURALIO
- TYKERB
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VOTRIENT
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY)

- XPOVIO (60 MG ONCE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- YONSA
- ZEJULA
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET
- ZYTIGA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A (6) Documentation of continuous therapy with the medication requested

ORAL PAH AGENTS

Products Affected

- *ambrisentan*
- *bosentan*
- LETAIRIS
- OPSUMIT
- ORENITRAM
- TRACLEER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 month for initial authorization and 12 months for continuation approvals
Other Criteria	Approved when all of the following inclusion criteria are met: (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Continuationof therapy: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

ORENCIA SQ

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 2 years
Prescriber Restrictions	Medication is being recommended by a rheumatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of either (1) inadequate response or inability to tolerate adalimumab (Humira) and etanercept (Enbrel) OR documentation demonstrating that a trial may be inappropriate

ORILISSA

Products Affected

- ORILISSA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months for 150mg tablet, 6 months for 200mg tablet
Other Criteria	Documentation is provided of BOTH of the following: 1) Documentation of ONE of the following, a) Inadequate response or inability to tolerate BOTH of the following i) one nonsteroidal anti-inflammatory drug and ii) one contraceptive OR b) Member has had surgical ablation to prevent recurrence, 2) Treatment duration does not exceed 24 months (150mg tablet) or 6 months (200mg tablet).

ORKAMBI

Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Diagnosis of CF other than those homozygous for the F508del mutation
Required Medical Information	If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
Age Restrictions	Deny if age is less than 2 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following: (1) Diagnosis of Cystic Fibrosis, (2) Patient is homozygous for the F508del mutation in the CFTR gene

OTEZLA

Products Affected

- OTEZLA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Recommended by Rheumatologist or Dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of psoriatic arthritis or plaque psoriasis AND (2) inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel)

OXERVATE

Products Affected

- OXERVATE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an ophthalmologist.
Coverage Duration	8 weeks
Other Criteria	

PALYNZIQ

Products Affected

- PALYNZIQ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Initial: 6 months, Continuation: Indefinite
Other Criteria	CONTINUATION CRITERIA: Documentation of a positive clinical response to Palynziq therapy

PART D VS EXCLUDED

Products Affected

- AURYXIA
- INTRAROSA
- OSPHENA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	

PDE INHIBITOR AGENTS FOR PAH

Products Affected

- ADCIRCA
- ALYQ
- REVATIO ORAL SUSPENSION RECONSTITUTED
- *tadalafil (pah)*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 months for initial approvals and 12 months for renewals
Other Criteria	Documentation of ALL of the following: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) inadequate response or inability to tolerate sildenafil RE-AUTHORIZATION CRITERIA: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

PREFERRED HEPATITIS C AGENTS

Products Affected

- EPCLUSA
- HARVONI
- *ledipasvir-sofosbuvir*
- MAVYRET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Hepatitis C Genotype
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	Criteria will be applied consistent with current AASLD/ IDSA guidance

PROLIA

Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary for the treatment OSTEOPOROSIS when BOTH of the following are met: (1) ONE of the following: (a) T-score less than or equal to -2.5 (b) history of osteoporotic fracture (e.g., vertebral, hip, non-vertebral) or (c) multiple risk factors for fracture, AND (2) ONE of the following: (a) inadequate response or inability to tolerate at least one other osteoporosis medicine (e.g., oral bisphosphonates, calcitonin, estrogens, selective estrogen receptor modulator (SERMs)) or (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted. For the treatment of OSTEOPENIA: (T-score less than -1.0, but greater than -2.5), with ONE of the following: (a) receiving adjuvant aromatase inhibitor therapy for breast cancer or (b) receiving androgen deprivation therapy for non-metastatic prostate cancer.

PULMONARY FIBROSIS AGENTS

Products Affected

- ESBRIET
- OFEV

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an appropriate specialist such as pulmonologist or lung transplant
Coverage Duration	12 months initial and reauthorization
Other Criteria	Diagnosis of idiopathic pulmonary fibrosis confirmed by high resolution CT scan or biopsy REAUTHORIZATION CRITERIA: BOTH of the following (1) stabilization from baseline or a less than 10% decline in forced vital capacity AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage

QUALAQUIN

Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Diagnosis of uncomplicated plasmodium falciparum malaria

RAVICTI

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Acute hyperammonemia. N-acetylglutamate synthase (NAGS) deficiency
Required Medical Information	
Age Restrictions	Deny if less than age 2 months
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of urea cycle disorder involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), or argininosuccinic acid synthetase (AAS) confirmed via enzymatic, biochemical, or genetic testing, (2) inadequate response or inability to tolerate sodium phenylbutyrate

REPATHA

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months Continuation 12 months
Other Criteria	INITIAL AUTHORIZATION: Diagnosis of either hyperlipidemia, homozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid) AND ONE of the following: (1) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (2) Inability to tolerate statin therapy as documented by one of the following: (a) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (b) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (c) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (d) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. CONTINUATION OF REPATHA: approved for 12 months if there is documentation of sustained reduction in LDL-C from baseline as defined by 25% reduction of LDL-C from baseline or sustained below 70 mg/dL.

RESPIRATORY ENZYMES

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED
- ZEMAIRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	IgA deficiency with known anti-IgA antibody
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when BOTH of the following are met: (1) low serum concentration of alpha-1 antitrypsin defined as less than 35 percent of normal (less than 80 mg/dL or less than 11 uM/L or less than 0.8 g/L) (2) the individual has progressive panacinar emphysema with a documented rate of decline in forced expiratory volume in 1 second (FEV 1)

RUZURGI

Products Affected

- RUZURGI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Patient is 6 to less than 17 years of age.(changed from row 4)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	90 days, indefinite for continuation.
Other Criteria	INITIAL CRITERIA: Both of the following: (1) Neurological symptoms persist after treatment of malignancy, when malignancy is present and (2) Documentation the member has moderate to severe weakness. CONTINUATION CRITERIA: Documentation is provided of a positive clinical response to therapy.

SAMSCA

Products Affected

- SAMSCA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	(1) patients who are unable to sense or appropriately respond to thirst, hypovolemic hyponatremia (2) concomitant use of strong CYP3A inhibitors
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by cardiologist, endocrinologist or nephrologist
Coverage Duration	Indefinite
Other Criteria	Documentation of a diagnosis of clinically significant hypervolemic or euvolemic hyponatremia and BOTH of the following (1) ONE of the following (a) serum sodium less than 125meq/L or (b) serum sodium 125-135 meq/L with symptoms (2) inadequate response or inability to tolerate therapies to control hyponatremia (ie fluid restriction, diuretics, demeclocycline)

SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by HIV specialist
Coverage Duration	48 weeks
Other Criteria	Diagnosis of wasting or cachexia associated with HIV

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by or in consultaton with an endocrinologist
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of (pituitary) Cushing's disease AND (2) pituitary surgery is not an option or has not been curative

SILDENAFIL

Products Affected

- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Documentation of concomitant nitrate use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV and BOTH of the following (a) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (b) Mean pulmonary artery pressure greater than or equal 25 mm Hg at rest or greater than 30 mm Hg with exertion. (2) diagnosis of secondary Raynaud's phenomenon and inadequate response or inability to tolerate a calcium channel blocker

SILIQ

Products Affected

- SILIQ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to the start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a dermatologist
Coverage Duration	Initial: 16 weeks Reauthorization: 1 year
Other Criteria	Documentation of ALL of the following: 1) plaque psoriasis and 2) inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate 3) member has been evaluated for depression and suicidal ideations using the PHQ-9 Reauthorization criteria BOTH of the following: 1) member has positive response to therapy 2) member has been evaluated for depression and suicidal ideations using the PHQ-9

SIMPONI

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by Rheumatologist, gastroenterologist, or dermatologist
Coverage Duration	Indefinite
Other Criteria	Ankylosing Spondylitis or Psoriatic Arthritis: inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Rheumatoid arthritis: BOTH of the following (1) inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate AND (2) concurrent therapy with methotrexate Ulcerative Colitis: inadequate response or inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Sirturo (bedaquiline) will be administered by directly observed therapy (DOT).
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Recommended by infectious disease specialist or pulmonologist
Coverage Duration	24 weeks
Other Criteria	Documentation of ONE of the following: (1) medication will be used in combination with at least 3 other drugs to which the patient's MDR-TB isolate has been shown to be susceptible in vitro OR (2) If in vitro testing results are unavailable, treatment will be initiated in combination with at least 4 other drugs to which the patient's MDR-TB isolate is likely to be susceptible.

SKYRIZI

Products Affected

- SKYRIZI (150 MG DOSE)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	If the patient's genotype is unknown, an FDA-cleared test must be used to detect the presence of CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test
Age Restrictions	Deny if age less than 12 years
Prescriber Restrictions	Prescribed by pulmonologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following (1) Diagnosis of Cystic Fibrosis, (2) One of the following: a) Member is homozygous for the F508del mutation, or b) Member has at least one tezacaftor/ivacaftor responsive mutation in the CFTR gene.

STELARA

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if age is less than 12 years
Prescriber Restrictions	Deny if not prescribed by Dermatologist, Gastroenterologist, or Rheumatologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when there is ONE of the following (1) psoriasis and ONE of the following (a) member 12 to 17 years of age: an inadequate response or inability to tolerate etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate (b) member 18 years of age and older: an inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate OR (2) psoriatic arthritis and an inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate OR (3) Crohn's Disease: documentation of inadequate response/inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate

SYLATRON

Products Affected

- SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	autoimmune hepatitis, hepatic decompensation
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by dermatologist or oncologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary when ONE of the following inclusion criteria is met:(1) use for adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy OR (2) documentation of continuous therapy with Peginterferon alfa-2b (Sylatron)

SYMDEKO

Products Affected

- SYMDEKO ORAL TABLET THERAPY PACK 50-75 & 75 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	If the patient's genotype is unknown, an FDA-cleared test must be used to detect the presence of CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test
Age Restrictions	Deny if age less than 6 years
Prescriber Restrictions	Prescribed by pulmonologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following (1) Diagnosis of Cystic Fibrosis, (2) One of the following: a) Member is homozygous for the F508del mutation, or b) Member has at least one tezacaftor/ivacaftor responsive mutation in the CFTR gene.

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of diagnosis of diabetes (Type 1 or Type 2) and both of the following: (1) inadequate response to optimal insulin monotherapy and (2) concurrent use of mealtime insulin

TAFAMIDIS

Products Affected

- VYNDAQEL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	12 months
Other Criteria	BOTH of the following are met: 1) Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) confirmed by one of the following: a) patient has a transthyretin (TTR) mutation (e.g., V122I), b) cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, or c) all of the following: echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, scintigraphy scan suggestive of cardiac TTR amyloidosis, and absence of light-chain amyloidosis, 2) One of the following: a) History of heart failure (HF), with at least one prior hospitalization for HF, or b) presence of clinical signs and symptoms of HF (e.g., dyspnea, edema), c) Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure, REAUTHORIZATION CRITERIA: 1) Documentation of positive clinical response to therapy, 2) Patient continues to have NYHA Functional Class I, II, or III heart failure, 3) Prescribed by or in consultation with a cardiologist.

TAKHZYRO

Products Affected

- TAKHZYRO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an allergist or immunologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ALL of the following criteria are met: (1) Diagnosis of hereditary angioedema (HAE) (2) history of laryngeal edema or airway compromise with an episode of HAE or a history of at least 2 HAE attacks per month, AND (3) inadequate response or inability to tolerate 17 alpha-alkylated androgens (e.g. danazol, oxandrolone, stanozolol) or anti-fibrinolytic agents (e.g. epsilon aminocaproic acid, tranexamic acid) for HAE prophylaxis

TALTZ

Products Affected

- TALTZ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to the start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by rheumatologist or dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of the following: plaque psoriasis or psoriatic arthritis and inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

TAVALISSE

Products Affected

- TAVALISSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation of baseline platelet count less than 30,000/mcL
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Prescribed by or in consultation with hematologist/oncologist
Coverage Duration	Initial and Continuation criteria is 12 months
Other Criteria	Approved when there is documentation of an inadequate response or inability to tolerate ONE of the following: 1) Corticosteroids, 2) Immunoglobulins, 3) Splenectomy, 4) Thrombopoietin receptor agonists (e.g., Nplate, Promacta), or 5) rituximab (Rituxan). Continuation criteria: Fostamatinib (Tavalisse) is re-approved when there is documentation of a positive clinical response to Tavalisse therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.

TEGSEDI

Products Affected

- TEGSEDI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documented presence of cardiac or renal manifestations, or motor, sensory, or autonomic neuropathy related to the hATTR amyloidosis with polyneuropathy (e.g., neuropathic pain, muscle weakness that affects daily living, orthostatic hypotension, diarrhea, nausea, vomiting, heart failure, arrhythmias, proteinuria, renal failure, vision disorders, such as vitreous opacity, dry eyes, glaucoma, or pupils with an irregular or scalloped appearance)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	16 months for initial and indefinite for continuation

PA Criteria	Criteria Details
Other Criteria	Documentation is provided of BOTH of the following are met: (1) Diagnosis of hATTR amyloidosis with polyneuropathy confirmed by molecular genetic testing that reveals pathogenic variation(s) in the TTR gene (e.g. variation of V30M), AND (2) Documentation of ONE of the following baseline ambulation parameters in either the Familial Amyloid Polyneuropathy (FAP) Stage or Polyneuropathy Disability (PND) Score (a) Stage 1 (unimpaired ambulation) or 2 (assisted ambulation) on the Familial Amyloid Polyneuropathy (FAP) staging tool, or (b) Score I, II, IIIa, or IIIb on the Polyneuropathy Disability (PND) scoring tool. CONTINUATION CRITERIA: (1) Documented improvement or stability in the signs and symptoms hATTR amyloidosis with polyneuropathy (e.g., neuropathic pain, muscle weakness that affects daily living, orthostatic hypotension, diarrhea, nausea, vomiting, heart failure, arrhythmias, proteinuria, renal failure, vision disorders, such as vitreous opacity, dry eyes, glaucoma, or pupils with an irregular or scalloped appearance), based on objective or standard evaluation scales, and (2) ONE of the following: (a) Stage 1 (unimpaired ambulation) or 2 (assisted ambulation) on the Familial Amyloid Polyneuropathy (FAP) staging tool, or (b) Score I, II, IIIa, or IIIb on the Polyneuropathy Disability (PND) scoring tool

TESTOSTERONE PRODUCTS

Products Affected

- ANDROGEL PUMP TRANSDERMAL GEL 20.25 MG/ACT (1.62%)
- ANDROGEL TRANSDERMAL GEL 20.25 MG/1.25GM (1.62%), 40.5 MG/2.5GM (1.62%)
- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml*
- *testosterone enanthate intramuscular solution*
- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*
- XYOSTED

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Treatment of Sexual or Erectile Dysfunction
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	For Hypogonadism: Diagnosis confirmed by ALL of the following: (1) Two early morning total testosterone levels below 300 ng/dL measured on separate occasions, (2) Normal Prolactin Level, and (3) physical or cognitive symptoms of testosterone deficiency (e.g. physical: fatigue, sleep disturbances, decreased activity, cognitive: depressive symptoms, cognitive dysfunction, loss of concentration, poor memory, irritability) and ONE of the following (1) negative history of prostate and breast cancer OR (2) Both of the following (a) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (b) documentation that the risk versus benefit has been assessed.

TOPICAL RETINOID PRODUCTS

Products Affected

- *adapalene external cream*
- *adapalene external gel*
- *adapalene external pad*
- *adapalene-benzoyl peroxide*
- AVITA
- *clindamycin-tretinoin*
- EPIDUO FORTE
- *tretinoin external*
- *tretinoin microsphere*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Cosmetic use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	

TREMFYA

Products Affected

- TREMFYA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to the start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of the following: plaque psoriasis and inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

UPTRAVI

Products Affected

- UPTRAVI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Not taken in combination with a prostanoid/prostacyclin analogue (e.g. epoprostenol, iloprost, treprostinil)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 month for initial authorization and 12 months for re-authorizations
Other Criteria	Approved when ALL of the following inclusion criteria are met: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV AND (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion AND (4) inadequate response or inability to tolerate TWO of the following (a) an endothelin receptor antagonist (Tracleer if naive to the class) (b) a phosphodiesterase inhibitor (sildenafil if naive to the class) (c) riocuguat (Adempas). RE-AUTHORIZATION CRITERIA: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with one of the following: (1) Oncologist (2) Dermatologist
Coverage Duration	12 months
Other Criteria	Documentation of a diagnosis of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy

VECAMYL

Products Affected

- VECAMYL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Uremia, glaucoma, organic pyloric stenosis, coronary insufficiency, recent myocardial infarction
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of moderately severe to severe essential hypertension or malignant hypertension AND (2) an inadequate response or inability to tolerate at least two antihypertensive medications in different classes

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists or potent immunosuppressants such as azathioprine or cyclosporine
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Recommended by a Gastroenterologist or Rheumatologist
Coverage Duration	Indefinite
Other Criteria	FOR RHEUMATOID ARTHRITIS/PSORIATIC ARTHRITIS: Documentation of ONE of the following: (1) inadequate response or inability to tolerate adalimumab (Humira) AND etanercept (Enbrel) or (2) documentation demonstrating that a trial may be inappropriate. For Ulcerative Colitis: documentation of inadequate response/inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate.

XENAZINE/AUSTEDO

Products Affected

- AUSTEDO
- *tetrabenazine*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a psychiatrist
Coverage Duration	3 month initial authorization for TD, indefinite for TD re-auth AND Chorea-Huntington's disease
Other Criteria	For diagnosis of Tardive dyskinesia (TD) documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Continuation of therapy: Documentation of positive clinical response to therapy.

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary necessary when there is documentation of ONE of the following diagnoses: (1) prevntion of skeletal related events in multiple myeloma or bone metastases from solid tumors OR (2) Giant cell tumor of the bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity OR (3) hypercalcemia of malignancy refractory to bisphosphonates

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if patient is less than 6 years
Prescriber Restrictions	Prescribed by Allergist, Dermatologist, Immunologist, or Pulmonologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review. Part D is medically necessary FOR DIAGNOSIS OF MODERATE TO SEVERE PERSISTENT ASTHMA: Documentation of ALL of the following: (1) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (2) The individual has a baseline serum IgE level of between 30 IU/mL and 1300 IU/mL AND (3) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). FOR DIAGNOSIS OF CHRONIC URTICARIA: Documentation of an inadequate response, contraindication or inability to tolerate ONE second-generation antihistamine at the maximally tolerated dose in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g.. montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second-generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine

XYREM

Products Affected

- XYREM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	recommended by a neurologist or sleep specialist
Coverage Duration	12 months (initial and reauthorization)
Other Criteria	Documentation of 1) cataplexy in narcolepsy OR 2) excessive daytime sleepiness in narcolepsy with inadequate response or inability to modafanil. REAUTHORIZATION CRITERIA: Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale) AND re-evaluated every 3 months

ZAVESCA

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of mild to moderate type 1 Gaucher disease AND enzyme replacement therapy is not a therapeutic option (e.g. because of allergy, hypersensitivity, or poor venous access).

ZORBTIVE

Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 weeks
Other Criteria	Used in conjunction with optimal management for short bowel syndrome, including specialized nutrition support

Index